The Latest Cardiac and Vascular News
KIRKLAND, Wash.–(BUSINESS WIRE)–Cardiac Dimensions®, a leader in the development of innovative and minimally invasive treatment modalities to address patients suffering from heart failure with functional mitral regurgitation (FMR), today announced that renowned interventional cardiologist Satya Shreenivas, MD, MBA has joined the company as Chief Medical Officer. “I have always been […]
KIRKLAND, Wash.–(BUSINESS WIRE)–Cardiac Dimensions®, a leader in the development of innovative, minimally invasive treatment modalities to address patients suffering from heart failure with functional mitral regurgitation (FMR), today announced that its Carillon Mitral Contour System® has received certification under Regulation (EU) 2017/745 (“MDR”). The MDR program is intended to ensure high standards […]
KIRKLAND, Wash.–(BUSINESS WIRE)–Cardiac Dimensions®, a leader in the development of innovative, minimally invasive treatment modalities to address heart failure and related cardiovascular conditions, today announced the appointment of Angie Swenson as Vice President of Clinical Operations. Ms. Swenson has spent most of the last 20 years leading clinical trials in […]
Funds Expected to Support Enrollment in U.S. Pivotal EMPOWER Trial and European Commercial Expansion for Carillon Mitral Contour System® KIRKLAND, Wash.–(BUSINESS WIRE)–Cardiac Dimensions®, a leader in the development of innovative, minimally invasive treatment modalities to address heart failure and related cardiovascular conditions, today announced it has closed a $35 million Series […]
Guidelines support the Carillon Mitral Contour System® for the treatment of heart failure patients with secondary functional mitral regurgitation KIRKLAND, Wash., Sept. 22, 2021 /PRNewswire/ — Cardiac Dimensions, a leader in the development of innovative, minimally invasive treatment modalities to address heart failure and related cardiovascular conditions, today announced the mention of their […]
International Study to Evaluate Innovative Minimally Invasive Treatment for Heart Failure With Early-Stage Functional Mitral Regurgitation KIRKLAND, Wash., Aug. 20, 2021 /PRNewswire/ — Cardiac Dimensions, a leader in the development of innovative, minimally invasive treatment modalities to address heart failure and related cardiovascular conditions, today announced the launch of the U.S. […]
On behalf of Cardiac Dimensions, please find key outcomes of the analysis “Percutaneous Mitral-Valve Annuloplasty Versus Optimal Medical Therapy in Patients with Secondary Mitral-Regurgitation and Severe Left-Ventricular Enlargement” published in this month’s JACC: Heart Failure. The manuscript can be viewed here: https://cardiacdimensions.com/wp-content/uploads/docs/Anker-Complete-Publication_May-2021.pdf Key outcomes of the analysis are as follows — in the Carillon […]
KIRKLAND, Wash., April 7, 2021 /PRNewswire/ — Cardiac Dimensions announced a published second individual patient data meta–analysis demonstrating clinically significant outcomes for the Carillon Mitral Contour System®. This publication, in addition to the several others recently published on the Carillon device, continues the series of excellent results for this transcatheter-based indirect annuloplasty device. […]
KIRKLAND, Wash., April 6, 2021 /PRNewswire/ — Cardiac Dimensions, a leader in the development of innovative, minimally invasive treatments for functional mitral regurgitation (FMR) in patients with heart failure, today announced the election of Robert White as an independent director to its Board of Directors. Mr. White is a veteran medical technology executive, innovator […]
Atrial functional mitral regurgitation (aFMR) is associated with left atrial (LA) and mitral annular dilatation most often caused by atrial fibrillation or heart failure with preserved ejection fraction (HFpEF). (A) Echocardiographic assessment, (B) functional mitral regurgitation classification, (C) New York Heart Association classification, and (D) mitral annulus diameter at baseline, […]
